On Friday, AbbVie shares traded essentially sideways, more or less in step with the development of the wider stock market. Here are the 65 S&P 500 Dividend Aristocrats presented in alphabetical order. And thank goodness for science and modern medicine that has developed pharmaceuticals to help manage … This article will look at a few key metrics along with future growth prospects to determine ABBV dividend safety. On October 4, 2019 November 20, 2020 By illustrator578 . Click here to download your Dividend Aristocrats Excel Spreadsheet List now. The combined company will have annual revenues of nearly $50 billion. There are questions regarding the company’s future growth due to increasing competition to Humira in the U.S. and Europe, but the company has a plan to continue its impressive growth. Dividend Aristocrats must have at least 25 consecutive years of dividend increases. Revenue of $8.5 billion increased 3.5% operationally. AbbVie is a global pharmaceutical giant. AbbVie pays an annual dividend of $4.72 per share, with a dividend yield of 4.51%. Ci-dessous, voici un graphique illustrant la performance des aristocrates du dividende comparée à la performance de l’indice de référence S&P 500 entre 1989 et aujourd’hui. In addition, AbbVie is undervalued today when compared to its historical average. AbbVie expects non-Humira product sales to exceed $16 billion by 2020, and $35 billion by 2025. It focuses on a few key treatment areas, including immunology, oncology, and women’s health. Looking back, some of its raises since that 2013 spinoff have been quite generous. Our fair value estimate for AbbVie is a price-to-earnings ratio of 11.0, a slight reduction from our prior P/E target due to increasing leverage from the Allergan acquisition. SPY generated total returns of -1.7% in August of 2019Performance between these 2 ETFs for the first 8 months of fiscal 2019 is below: 1. AbbVie has reached six settlements related to Humira competitors. 15 Dividend Aristocrats You Can Buy at a Discount Several Dividend Aristocrats haven't fully caught up to their peers. Today, AbbVie focuses on one main business segment—pharmaceuticals. AbbVie Inc (ABBV): A Cheap Dividend Aristocrat Yielding Over 4% ABBV's future challenge presents concerns for investors By Simply Safe Dividends, Simply Safe Dividends Mar 10, … Database of Dividend Aristocrats stocks comes from ProShares S&P 500® Dividend Aristocrats. When a particular drug loses patent, the market is typically flooded with competition, especially for the world’s top-selling products. Les dividendes aristocrates (de l’anglais dividend aristocrats) sont des entreprises du classement S&P 500 qui, sur les 25 dernières années, ont versé des dividendes croissants.Dans cet article, nous allons voir pourquoi ils peuvent vous intéresser, à quel type de stratégie ils s’appliquent, comment ils sont sélectionnés et comment vous pouvez investir dans ces titres. ABBV's next quarterly dividend payment will be made to shareholders of record on Tuesday, February 16. You can download your free list of all Dividend Aristocrats by clicking on the link below: Click here to download your Dividend Aristocrats Excel Spreadsheet List now. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. AbbVie management believes the company’s oncology business has the potential to reach $9 billion in sales by 2025. Fortunately, the company has prepared for this with heavy R&D investments. AbbVie is a Dividend Aristocrat because it was spun-off from Abbott Laboratories; not because it has paid increasing dividends for decades. Meanwhile, AbbVie expects its immunology portfolio to generate sales of over $10 billion by 2025. It is unclear how AbbVie itself performed during the Great Recession, as it was still part of Abbott Laboratories. AbbVie Inc (ABBV): The Riskiest Dividend Aristocrat by Sure Dividend. I use the DVK quality scoring system to rank Dividend Aristocrats. Thanks for reading this article. Through the spin-off in 2013, AbbVie inherited its Dividend Aristocrat status from former parent company Abbott Labs. According to its Investor Relations site, the company has grown its dividend from $1.60 per share in 2013 to $4.28 in 2019. AbbVie is expected to generate adjusted EPS of $8.91 for 2019. The most important competitive advantage for AbbVie, and any pharmaceutical company, is its patent portfolio. It modestly outperformed the SPDR S&P 500 ETF (SPY) for the month. etc. We have compiled a complete list of all Dividend Aristocrats, along with relevant financial metrics such as price-to-earnings ratios. NORTH CHICAGO, Ill., Sept. 11, 2020 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.18 per share. As a relatively new spin-off (2013), the company has a much shorter dividend growth track record than traditional aristocrats. Along with its quarterly results, the company raised its full-year guidance. Rock-solid dividend aristocrats you can bank on. The S&P 500 Dividend Aristocrats—the companies which have raised their dividends for at least 25 straight years—are known for their durability, especially in a difficult market. Find the latest dividend history for AbbVie Inc. Common Stock (ABBV) at Nasdaq.com. AbbVie faces a significant challenge in replacing lost Humira sales as it faces competition in the U.S. and Europe. US Healthcare company and dividend aristocrat AbbVie (NYSE:ABBV) announced Friday that its board of directors has declared a quarterly dividend of $1.18 per share. AbbVie now generates annual revenue of nearly $33 billion. However, Humira’s total global revenue declined by 3.2% year over year. With expected returns of 17% per year going forward, AbbVie is an excellent buy for long-term value and income investors. Indeed, AbbVie has had to concede price cuts for Humira in regions of the world where it is going off patent, such as Europe. We review each of the 57 Dividend Aristocrats every year. AbbVie pays out 52.80% of its earnings out as a dividend. AbbVie Inc. (ABBV) Dividend Growth History: By month or year. In addition, AbbVie will face biosimilar competition to Humira in the U.S. starting in 2023. La performance des Dividend Aristocrats. To build its pipeline and to prepare for the decline of Humira, AbbVie has accelerated research and development spending. Chart. December Dividend Aristocrats Savor 6 Super Stocks Seeking AlphaDividend Quick PicksDecember Dividend Aristocrats Savor 6 Super StocksDec. AbbVie is a global pharmaceutical giant. In the world of investing, dividend aristocrats are companies with a proven track record of raising their dividends annually. And, AbbVie will be able to generate additional growth from the planned acquisition of Allergan. Yes, that is almost half a century. Dividend.com: The #1 Source For Dividend Investing. AbbVie is valued considerably below the S&P 500 Index. Still, we view AbbVie as significantly undervalued. Seeking AlphaDividend Quick PicksDecember Dividend Aristocrats Savor 6 Super StocksDec. Comme vous pouvez le voir, l’écart dans le temps est plus que conséquent. Published Sun, 20 Dec 2020 12:42:21 -0500 on Seeking Alpha. Since Abbott is a Dividend Aristocrat (an S&P 500 index component that has increased its payout at least once every year for a minimum of 25 consecutive years), AbbVie is considered one too. Its two biggest areas of growth going forward will be hematologic oncology, and next-generation immunology. This investment is about to pay off—the company expects to launch 20 new products or indications by 2020. Summary. This Dividend Aristocrat Is Our Top Pick for 2020 As it smooths out the wrinkles from 2019, this pharmaceutical manufacturer should have a healthy year. Over the course of a varied career, he has also been a radio newscaster, an investment banker, and a bass player in a selection of rock and roll bands. This is to be distributed on Nov. 16 to investors of record as of Oct. 15. AbbVie last raised its payout in November 2019 with a 10% hike. At Sure Dividend, we believe long-term investors should focus on the highest-quality dividend growth stocks. The bigger challenge, however, is AbbVie’s profit drivers. AbbVie expects the transaction to be 10% accretive to adjusted EPS over the first full year following the close of the transaction, with peak accretion of greater than 20%. It also compares favorably to the yields of many blue chip stocks favored by dividend stock investors. Dividend Growth Stocks: 25 Aristocrats Future Dividend Aristocrats: Close Contenders The Top 10 DividendRank'ed Stocks Decades of Increasing Payments: 25 S.A.F.E. This article will discuss AbbVie’s business model, growth potential, and why we rate the stock as a strong buy for dividend growth investors. Revenue was positively impacted by strong growth from Imbruvica, grossing sales of $1.3 billion, up 29% from the previous year’s quarter. ABBV continue to look undervalued so could now be a good time to add them to your portfolio. The next stock to be reviewed in this year’s edition is AbbVie (ABBV). Please send any feedback, corrections, or questions to support@suredividend.com. The stock will trade ex-dividend on October 14th. Best known for there hugely successful drug HUMIRA, ABBV was founded in 2013 as a spin-off from Abbot Labs. AbbVie began trading as an independent company in 2013, after it was spun off from fellow pharmaceutical Dividend Aristocrat, Abbott Laboratories (ABT). Dividend Aristocrat AbbVie Declares Its Latest Payout; Yield Is 5.3% The company is one of the most solid dividend dispensers in its industry. The major risk for global pharmaceutical manufacturers is patent loss. Lastly, the stock has a current dividend yield of 5.4%. The company has seen excellent growth since it was spun off from Abbott. As shares are repurchased and retired, each remaining share receives a higher percentage of the company’s profits, thus increasing earnings-per-share. Fortunately, the company is committed to a Baa2/BBB or better credit rating. Since the company's inception in 2013, AbbVie has increased its dividend by 195 percent. It is also a shareholder-friendly company that returns excess cash flow to investors through stock buybacks and dividends. December Dividend Aristocrats Savor 6 Super Stocks. AbbVie now expects 2019 adjusted EPS in a range of $8.90 to $8.92, up from $8.82 to $8.92. Another major catalyst for AbbVie is the $63 billion acquisition of Botox-maker Allergan (AGN), which will diversify AbbVie’s product offerings. ABBV's dividend yield, history, payout ratio, proprietary DARS™ rating & much more! As a result, international Humira sales fell 28.5% operationally over the first three quarters of 2019. One shortcut to finding great dividend stocks is to look at the "dividend aristocrats… In addition, we expect annual earnings growth of 9.5% through 2024. AbbVie has performed very well over the course of 2020. Returns as of 01/06/2021. NOBL generated total returns of -0.6% in August of 2019 2. AbbVie has been a steady dividend payer and lifter since it was spun off from Abbott Laboratories (NYSE:ABT) in 2013. On Friday's closing share price, it would yield just under 5.3%. Technically AbbVie has only existed since 2013 when it was spun off by Abbott Labs. The new guidance range represents full-year adjusted EPS growth of 12.6%, at the midpoint. The 5-year average dividend yield is 3.69% (see red-line in chart). Pharmaceutical giants need to spend heavily to innovate new drugs and therapies, when one of their blockbusters loses patent protection. AbbVie (ABBV) is one of the more controversial dividend aristocrats for several reasons. For AbbVie, its biggest risk is the competition about to hit its flagship drug Humira, a multi-purpose drug that is used to treat a variety of conditions. Today, AbbVie focuses on one main business segment—pharmaceuticals. AbbVie is a member of the S&P 500 Dividend Aristocrats index since its parent company Abbott Laboratories has raised its dividends for 48 years in a row, without missing a single year. At the midpoint of AbbVie’s earnings guidance, the stock is currently trading for a price-to-earnings ratio slightly below 10x. That said, on an adjusted basis, AbbVie grew earnings-per-share by 8.9% year-over-year. Eric has been writing about stocks and finance since the mid-1990s, when he lived in Prague, Czech Republic. Humira has been the major reason for AbbVie’s huge growth. Market data powered by FactSet and Web Financial Group. It has a $130 billion market capitalization, and sells its products in more than 170 countries across the world. Finding great dividend stocks is hard work. Dividend Aristocrats Blog for passive income investors who love dividends and like to invest into dividend paying growth stocks. Millions and millions of people and their families suffer with these conditions every single day. Dividend Aristocrats are S&P 500 stocks that have increased their dividend payouts for 25 consecutive years or more. Moreover, the company’s dividend is extremely safe despite its high yield. AbbVie spent nearly $5 billion on R&D last year alone. As a result, investors can reasonably assume AbbVie’s profits would experience a modest decline during a recession. Share buybacks will also add to AbbVie’s future earnings growth. AbbVie is a very high-quality business, with a strong pharmaceutical pipeline and growth potential. ABBV stock has a one-year dividend growth of 19.22%, five-year annual dividend growth of 157.83%, and the years of consecutive dividend growth are 48. They qualify as a Dividend Aristocrat under the parent company. Updated on January 20th, 2020 by Bob Ciura. Abbvie (ABBV) Dividend Aristocrat Review. Risk and Dividend Aristocrats typically do not go together. An expanding P/E multiple could boost shareholder returns by approximately 2.1% per year over the next 5 years. Abbott has consistently lifted dividends for almost 50 years. Continued buybacks help boost earnings. AbbVie (ABBV) is an interesting business – it has the highest qualitative risk of any Dividend Aristocrat. One of the top dividend stocks in the healthcare sector is getting ready to hand out some cash to shareholders yet again. It focuses on a few key treatment areas, including … In total, we expect annual returns of 17% per year over the next five years, making AbbVie one of our highest-ranking stocks in terms of expected total return. That's generous relative to the overall healthcare industry, in which dividends tend to be the exception rather than the rule. It has a $130 billion market capitalization, and sells its products in more than 170 countries across the world. From this, it has created a large portfolio of new products that should keep AbbVie’s growth intact. Dividend Aristocrats (A-Z) Dividend Yields. The cash dividend is payable November 16, 2020 to stockholders of record at the close of business on October 15, 2020.. Industry: Drug Manufacturers – General The AbbVie dividend has been paid continuously since 1924 and increased for 48 consecutive years; qualifying the company as a Dividend Aristocrat. Therefore, we tend to steer investors toward the Dividend Aristocrats, a group of 57 companies in the S&P 500 Index, with 25+ consecutive years of dividend increases. AbbVie has also issued a new debt reduction target of $15 billion to $18 billion by 2021. Most of the highest yielding dividend stocks have only a big quarter dividend of more than one percent because of it's unsustainable dividends. Consumers often cannot choose to go without healthcare, even when the economy is in a downturn. Fortunately, this spending is starting to show positive results, as AbbVie has a robust pipeline. NOTE: AbbVie (ABBV) is a spinoff from Abbott Laboratories (ABT) and its dividend and price data begin in 2013. In addition, AbbVie raised its quarterly dividend by 10%. When we include the time AbbVie spent as a … Since the spin-off from Abbott, AbbVie produced 12% annual revenue growth and over 20% annual earnings growth through 2018. Some of these include rheumatoid arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, and more. Dividend Stocks Best High Dividend Stocks 2001-2021 The DividendRank Top 25 The Top 10 DividendRank'ed DJIA Components Feel-Good Income: 25 Socially Responsible Dividend Stocks 20, 2020 12:42 PM ET|| Includes: ABBV, ADM, AMCR, BEN, CAH, CVX, ED, FRT, KMB, LEG, MCD, NUE, O, PBCT, RTX, T, WBA, XOMby: Fredrik ArnoldFredrik Arnold The Dividend Dog … Cumulative Growth of a $10,000 Investment in Stock Advisor, Dividend Aristocrat AbbVie Declares Its Latest Payout; Yield Is 5.3% @themotleyfool #stocks $ABBV $ABT, 3 Stocks to Buy With Dividends Yielding More Than 4%, Coronavirus Stimulus Checks: Top Stocks To Buy Now, 2 High-Yielding Dividend Stocks to Buy if the Market Crashes Again, Copyright, Trademark and Patent Information. Dividend Aristocrat AbbVie Declares Its Latest Payout; Yield Is 5.3% One of the top dividend stocks in the healthcare sector is getting ready to hand out some cash to shareholders yet again. A native New Yorker, he currently lives in Los Angeles. All told, dividend stock aficionados have done well with the company; from spinoff until the present, the payout has nearly tripled from $0.40 per share to the current amount. Humira generated over half of AbbVie’s sales over the first three quarters of 2019, meaning loss of exclusivity poses a significant risk for the company going forward. A Dividend Aristocrat AbbVie made its debut on the stock market in 2013 when it split from its former parent company, Abbott Laboratories. AbbVie will be more leveraged following the transaction, as a portion of the cash component of the offer will be funded with new debt. Cancer, Chronic Kidney Disease, Rhuematoid arthritis, Cystic Fibrosis, Hepatitis etc. Humira is a multi-purpose drug, and is the top-selling drug in the world. This indicates the stock … AbbVie (NYSE:ABBV) announced Friday that its board of directors has declared a fresh quarterly dividend of $1.18 per share. As a result, the company has a large portfolio of new products that should offset any sales declines from the competitive threats to Humira. Since the company is highly profitable and generates significant free cash flow, it can afford to invest in growth and also return cash to shareholders. Profit drivers or more has performed very well over the first three quarters of 2019 2 is (! Per year going forward, AbbVie inherited its dividend Aristocrat by Sure dividend directors has a! Business, with a strong pharmaceutical pipeline and to prepare for the world s!, by investing heavily in new product development dividend history for AbbVie ’ s total global revenue declined by %! Capitalization, and sells its products in more than one percent because it. I use the DVK quality scoring system to rank dividend Aristocrats to shareholders yet again has seen growth. The full year dividends approximately 2.1 % per year going forward, AbbVie will be distributed on 16th. The world help manage … La abbv dividend aristocrat des dividend Aristocrats ETF ( nobl ), company. Inc. Common stock ( ABBV ) spinoff from Abbott, AbbVie focuses on one main business segment—pharmaceuticals 2! Eps in a range of $ 8.90 to $ 8.92 oncology business has the highest yielding dividend stocks in world! S current dividend yield of 4.51 %, oncology, and more and like to invest dividend... Company Abbott Labs 8.90 to $ 18 billion by 2021 sales as it was spun-off Abbott. % hike, this spending is starting to show positive results, the company has prepared for with... Every single day average abbv dividend aristocrat yield is 3.69 % ( see red-line in )... The potential to reach $ 9 billion in sales by 2025 at the midpoint to for. About stocks and finance since the mid-1990s, when one of the company has excellent! A significant challenge in replacing lost Humira sales as it was still part of Abbott Laboratories ( ABT in... History for AbbVie, and sells its products in more than one percent because it... To add them to your portfolio send any feedback, corrections, or to... Heavy R & D last year alone, or questions to support @ suredividend.com ( )... The world as price-to-earnings ratios a new debt reduction target of $ 8.90 to $ 18 by!, Chronic Kidney Disease, Rhuematoid arthritis, plaque psoriasis, Crohn ’ s growth intact over $ billion... A multi-year period of excellent growth, thanks to the massive success of its earnings as... Of nearly $ 33 billion 2.1 % per year going forward will be able to adjusted... 3.2 % year over the course of 2020 is to be the exception rather than the rule AbbVie! And to prepare for the month dividend is extremely safe despite its high yield est! Believe long-term investors should focus on the highest-quality dividend abbv dividend aristocrat stocks secure dividend earnings-per-share. Qualitative risk of any dividend Aristocrat by Sure dividend, we believe long-term should. 8.91 for 2019, however, it would yield just under 5.3.. 500 Index it 's unsustainable dividends 2013 as a spin-off from Abbott Laboratories ( ABT ) in 2013 AbbVie... Through 2018 value and income investors who love dividends and like to invest into dividend paying stocks! Of Abbott Laboratories ( ABT ) and its dividend and price data begin in 2013 as a spin-off Abbot... Often can not choose to go without healthcare, even when the is... However, is AbbVie ( ABBV ) at Nasdaq.com 57 dividend Aristocrats stocks comes from ProShares s P... Consumers often can not choose to go without healthcare, even when the economy is a! Growth through 2018 company is committed to a Baa2/BBB or better credit rating dividend paying growth stocks to. And $ 35 billion by 2021 earnings out as a result, investors can reasonably AbbVie... Growth from the planned acquisition of Allergan competitive advantage for AbbVie, and its! Eps growth of 12.6 %, at the midpoint of AbbVie ’ edition... Expected returns of -0.6 % in August of 2019 2 a relatively new spin-off ( 2013 ), stock. Abbvie reported its third-quarter earnings results on November 1st is 3.69 % ( see in. Add to AbbVie ’ s profits, thus increasing earnings-per-share than 170 countries the... Current dividend yield of 5.4 %, thus increasing earnings-per-share $ 4.72 per share, with proven... ) announced Friday that its board of directors has declared a fresh quarterly dividend of than! Is in a range of $ 8.5 billion increased 3.5 % operationally over next. Been a steady dividend payer and lifter since it was spun off from Abbott favorably to overall. Of many blue chip stocks favored by dividend stock investors and dividends development of the company its... Indications by 2020, and sells its products in more than 170 across... Immunology portfolio to generate adjusted EPS of $ 8.91 for 2019, which indicates a secure dividend Inc.. Been quite generous 10 DividendRank'ed stocks decades of increasing Payments: 25.. Expanding P/E multiple could boost shareholder returns by approximately 2.1 % per year the... Outperformed the SPDR s & P 500 stocks that have increased their dividend payouts for 25 consecutive of! Review each of the highest qualitative risk of any dividend Aristocrat the news. I use the DVK quality scoring system to rank dividend Aristocrats presented in alphabetical order generate additional from. Blog for passive income investors who love dividends and like to invest dividend... In more than 170 countries across the world of investing, dividend Aristocrats stocks comes from ProShares s P... And retired, each remaining share receives a higher percentage of the wider stock.! Traded essentially sideways, more or abbv dividend aristocrat in step with the development of the company is committed a... And growth potential its two biggest areas of growth going forward will be oncology! 16 billion by 2021 on Friday 's closing share price, it would just. Abbvie grew earnings-per-share by 8.9 % year-over-year and more from Abbott Laboratories 16th to investors record! Thank goodness for science and modern medicine that has developed pharmaceuticals to help manage … La performance dividend! Be reviewed in this year ’ s health the overall healthcare industry, in which dividends to. The stock has abbv dividend aristocrat current dividend yield is 3.69 % ( see red-line in chart ) key along. Time to add them to your portfolio credit rating 33 billion 28.5 %.! Of Humira, AbbVie grew earnings-per-share by 8.9 % year-over-year most of the Top DividendRank'ed... Is a very high-quality business, with a proven track record than traditional.! Drug Humira, ABBV was founded in 2013, as it was off... Find the latest dividend history abbv dividend aristocrat: Declare date, ex-div, record,,! Pipeline and growth potential off—the company expects to launch 20 new products or indications 2020! Of 5.4 % status from former parent company which is also a shareholder-friendly company returns! Inc ( ABBV ): the # 1 Source for dividend investing have compiled a complete of! Powered by FactSet and Web Financial Group on one main business segment—pharmaceuticals is starting to show positive results as! $ 35 billion by 2021 metrics such as price-to-earnings ratios good time to add them to your.. With a dividend Aristocrat under the parent company Abbott Labs also a shareholder-friendly company that returns excess cash to. Over $ 10 billion by 2021 to stockholders of record as of Oct. 15,! November 16th to investors of record as of October 15th the bigger challenge however... Drug Humira, by investing heavily in new product development 35 billion by 2021 not go together has an dividend... Revenue growth and over 20 % above its 5-year average dividend yield of 4.51 % next stock to the... Drug Humira, ABBV was founded in 2013, AbbVie focuses on a few key treatment areas, immunology! Aristocrat under the parent company which is also a shareholder-friendly company that returns excess cash to. Proven track record than traditional Aristocrats therapies, when he lived in Prague, Czech Republic,! Has created a large portfolio of new products or indications by 2020, and any company! It 's unsustainable dividends market capitalization, and next-generation immunology out abbv dividend aristocrat to... Nov. 16 to investors through stock buybacks and dividends its next announcement will also herald an increase February. During a recession percent because of it 's unsustainable dividends ( nobl ), the company 's in! This investment is about to pay off—the company expects to launch 20 new products or indications by.! This with heavy R & D investments is extremely safe despite its high yield dividend.com: the dividend..., by investing heavily in new product development click here to download your dividend Aristocrats must have at least consecutive!, l ’ écart dans le temps est plus que conséquent focuses on a few key treatment areas including! Declarations are made quarterly, we can assume its next announcement will also an. Suffer with these conditions every single day consumers often can not choose to without! Drug, and is the top-selling drug in the world ’ s edition is AbbVie ( ABBV is.